PRAX Praxis Precision Medicines, Inc.
FY2025 10-K
Praxis Precision Medicines, Inc. (PRAX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 19, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Precision neuroscience biopharma developing therapies for CNS disorders from genetic epilepsies via two platforms, Cerebrum™ (small molecules) and Solidus™ (antisense oligonucleotides)
- • New emphasis on clinical development with four clinical-stage candidates; submitted NDAs for ulixacaltamide (essential tremor) and relutrigine (SCN2A-DEE, SCN8A-DEE)
Management Discussion & Analysis
- • No revenues reported; focused on R&D and pre-commercial activities with expected substantial operating expense increases
- • Operating losses expected to grow due to advancing clinical trials, commercialization prep, and infrastructure buildout; no margin % disclosed
Risk Factors
- • Regulatory risk: ongoing FDA review of NDAs for ulixacaltamide (essential tremor) and relutrigine (SCN2A and SCN8A DEEs) with uncertain approval timing or outcome
- • Macroeconomic exposure: cash runway extends into 2028 but risks of faster cash burn due to increased R&D, clinical trials, or unexpected costs
Financial SummaryXBRL
Revenue
$0
Net Income
-$303M
ROE
-34.5%
Total Assets
$938M
EPS (Diluted)
$-13.48
Operating Cash Flow
-$249M
Source: XBRL data from Praxis Precision Medicines, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Praxis Precision Medicines, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.